Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of pegaptanib sodium (Macugen) on uveitic cystoid macular oedema: exploratory study
2007-000705-30Phase 4Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Mar 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaptanib sodium in cystoid macular edema (CME), sponsored by Moorfields Eye Hospital. Primary endpoint: Reduction of macular thickness. Started Mar 2007; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on 2007-000705-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000705-30.